MedTrace Logo

Corticosteroid Against Saline Injections for Thumb Osteoarthritis (CASITOA)

NCT06401317 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-01-22

No results posted yet for this study

Summary

Thumb osteoarthritis or trapeziometacarpal osteoarthritis (TMO) is a common and painful form of hand arthritis that limits thumb mobility and hand function, affecting patients' quality of life. Although corticosteroids injections are a typical treatment, their effectiveness has been challenged, and side effects have been reported. Recent studies suggest that saline injections, usually considered inactive, might be a viable treatment option. The primary goal of this study is to compare the effectiveness of saline injections versus corticosteroids injections in reducing TMO-related pain and improving hand function. In this study, 40 people with TMO will be randomly assigned to receive either a corticosteroids or a saline injection, without them or the doctors performing the injection knowing which one was administered (double blind). If saline injections prove more effective, they could provide a less harmful and cheaper therapeutic alternative for TMO patients.

Conditions

  • Trapeziometacarpal Osteoarthritis

Interventions

DRUG

Saline Solution (NaCl 0,9%)

Ultrasound/fluoroscopy-guided intra-articular injection of 0.25ml of 0.9% saline solution.

DRUG

Triamcinolone Acetonide

Ultrasound-guided intra-articular injection 0.25ml (10 mg) of triamcinolone.

Sponsors & Collaborators

  • Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal

    collaborator OTHER

  • McGill University

    collaborator OTHER

  • Université de Montréal

    collaborator OTHER

  • Centre hospitalier de l'Université de Montréal (CHUM)

    collaborator OTHER

  • Centre de Recherche du Centre Hospitalier de l'Université de Montréal

    collaborator OTHER

  • Université du Québec à Trois-Rivières

    lead OTHER

Principal Investigators

  • Tokiko Hamasaki, PhD · Université du Québec à Trois-Rivières

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-04
Primary Completion
2027-12-31
Completion
2028-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06401317 on ClinicalTrials.gov